FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282384> ?p ?o ?g. }

• W4379282384 endingPage "4007" @default.
• W4379282384 startingPage "4007" @default.
• W4379282384 abstract "4007 Background: Biliary tract cancer (BTC) is an aggressive malignancy with a poor prognosis, and current treatment options for advanced BTC are limited, with second-line therapy, FOLFOX and S-1 offering an objective response rate (ORR) of 5.0% and 7.5%, respectively. Up to 20% of BTCs overexpress human epidermal growth factor receptor 2 (HER2). Tucatinib (TUC) is a highly selective HER2-directed TKI approved for HER2-positive (HER2+) metastatic breast and colorectal cancer. Discussed here are the efficacy and safety results of TUC combined with Trastuzumab (Tras) in pts with previously treated HER2+ metastatic BTC. Methods: SGNTUC-019 (NCT04579380) is an open-label phase 2 basket study evaluating efficacy, safety, and tolerability of TUC and Tras in pts with HER2-altered solid tumors. Pts in the BTC cohort had been previously treated with and progressed after ≥1 line of systemic therapy for metastatic disease. Eligible pts had locally determined HER2+ (defined as HER2 overexpression determined by immunohistochemistry [IHC] 3+ or HER2 amplification determined by in situ hybridization assay or next-generation sequencing) metastatic BTC. Pts were treated on a 21-day cycle with TUC (300 mg orally twice a day) and Tras (8 mg/kg IV followed by 6 mg/kg every 3 wks). Disease status was determined based on RECIST v1.1 with assessments performed every 6 wks for 24 wks and every 12 wks thereafter. The primary endpoint is confirmed objective response rate (cORR) per investigator assessment. Secondary endpoints include overall survival (OS), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and safety. Results: Thirty pts were enrolled in the BTC cohort as of data cutoff date of 30 Nov 2022. The median duration of follow-up was 8.3 months. cORR was 46.7% (90% CI, 30.8, 63.0), with 14 responses including 1 complete and 13 partial responses. Median DOR was 6.0 months (90% CI, 5.5, not estimable). DCR was 76.7% (n=23; 90% CI, 60.6, 88.5), and median PFS was 5.5 months (90% CI, 3.9, 8.1). At data cutoff, 13 (43.3%) patients had died, and the 12-months OS rate was 53.8% (90% CI, 35.2, 69.1%). Overall, the most common treatment-emergent adverse events (TEAEs) reported were pyrexia (43.3%) and diarrhea (40.0%). Grade ≥3 TEAEs were reported in 18 (60.0%) of 30 pts; however, only 6 (20.0%) and 2 (6.7%) of these pts had Grade ≥3 TEAEs related to TUC and Tras, respectively. Two (6.7%) pts discontinued TUC due to TEAEs, cholangitis and liver disorder. No deaths were due to TEAEs. Conclusions: The combination of TUC and Tras was well tolerated in pts with previously treated HER2+ metastatic BTC. The observed antitumor activity supports the combination of TUC and Tras as a future chemotherapy-free treatment option for this population with historically poor outcomes. Clinical trial information: NCT04579380 ." @default.
• W4379282384 created "2023-06-05" @default.
• W4379282384 creator A5003060935 @default.
• W4379282384 creator A5013994958 @default.
• W4379282384 creator A5014611244 @default.
• W4379282384 creator A5017122759 @default.
• W4379282384 creator A5021359849 @default.
• W4379282384 creator A5022876688 @default.
• W4379282384 creator A5026351538 @default.
• W4379282384 creator A5033085910 @default.
• W4379282384 creator A5038101792 @default.
• W4379282384 creator A5038382774 @default.
• W4379282384 creator A5043723479 @default.
• W4379282384 creator A5054676638 @default.
• W4379282384 creator A5057657763 @default.
• W4379282384 creator A5060572768 @default.
• W4379282384 creator A5065581439 @default.
• W4379282384 creator A5074891676 @default.
• W4379282384 creator A5084847095 @default.
• W4379282384 creator A5084909001 @default.
• W4379282384 creator A5085697580 @default.
• W4379282384 date "2023-06-01" @default.
• W4379282384 modified "2023-10-17" @default.
• W4379282384 title "Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study." @default.
• W4379282384 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.4007" @default.
• W4379282384 hasPublicationYear "2023" @default.
• W4379282384 type Work @default.
• W4379282384 citedByCount "2" @default.
• W4379282384 countsByYear W43792823842023 @default.
• W4379282384 crossrefType "journal-article" @default.
• W4379282384 hasAuthorship W4379282384A5003060935 @default.
• W4379282384 hasAuthorship W4379282384A5013994958 @default.
• W4379282384 hasAuthorship W4379282384A5014611244 @default.
• W4379282384 hasAuthorship W4379282384A5017122759 @default.
• W4379282384 hasAuthorship W4379282384A5021359849 @default.
• W4379282384 hasAuthorship W4379282384A5022876688 @default.
• W4379282384 hasAuthorship W4379282384A5026351538 @default.
• W4379282384 hasAuthorship W4379282384A5033085910 @default.
• W4379282384 hasAuthorship W4379282384A5038101792 @default.
• W4379282384 hasAuthorship W4379282384A5038382774 @default.
• W4379282384 hasAuthorship W4379282384A5043723479 @default.
• W4379282384 hasAuthorship W4379282384A5054676638 @default.
• W4379282384 hasAuthorship W4379282384A5057657763 @default.
• W4379282384 hasAuthorship W4379282384A5060572768 @default.
• W4379282384 hasAuthorship W4379282384A5065581439 @default.
• W4379282384 hasAuthorship W4379282384A5074891676 @default.
• W4379282384 hasAuthorship W4379282384A5084847095 @default.
• W4379282384 hasAuthorship W4379282384A5084909001 @default.
• W4379282384 hasAuthorship W4379282384A5085697580 @default.
• W4379282384 hasConcept C121608353 @default.
• W4379282384 hasConcept C126322002 @default.
• W4379282384 hasConcept C143998085 @default.
• W4379282384 hasConcept C197934379 @default.
• W4379282384 hasConcept C203092338 @default.
• W4379282384 hasConcept C2775930923 @default.
• W4379282384 hasConcept C2776694085 @default.
• W4379282384 hasConcept C2778260052 @default.
• W4379282384 hasConcept C2778375690 @default.
• W4379282384 hasConcept C2778822529 @default.
• W4379282384 hasConcept C2779786085 @default.
• W4379282384 hasConcept C2779984678 @default.
• W4379282384 hasConcept C2780962732 @default.
• W4379282384 hasConcept C526805850 @default.
• W4379282384 hasConcept C530470458 @default.
• W4379282384 hasConcept C535046627 @default.
• W4379282384 hasConcept C71924100 @default.
• W4379282384 hasConcept C90924648 @default.
• W4379282384 hasConceptScore W4379282384C121608353 @default.
• W4379282384 hasConceptScore W4379282384C126322002 @default.
• W4379282384 hasConceptScore W4379282384C143998085 @default.
• W4379282384 hasConceptScore W4379282384C197934379 @default.
• W4379282384 hasConceptScore W4379282384C203092338 @default.
• W4379282384 hasConceptScore W4379282384C2775930923 @default.
• W4379282384 hasConceptScore W4379282384C2776694085 @default.
• W4379282384 hasConceptScore W4379282384C2778260052 @default.
• W4379282384 hasConceptScore W4379282384C2778375690 @default.
• W4379282384 hasConceptScore W4379282384C2778822529 @default.
• W4379282384 hasConceptScore W4379282384C2779786085 @default.
• W4379282384 hasConceptScore W4379282384C2779984678 @default.
• W4379282384 hasConceptScore W4379282384C2780962732 @default.
• W4379282384 hasConceptScore W4379282384C526805850 @default.
• W4379282384 hasConceptScore W4379282384C530470458 @default.
• W4379282384 hasConceptScore W4379282384C535046627 @default.
• W4379282384 hasConceptScore W4379282384C71924100 @default.
• W4379282384 hasConceptScore W4379282384C90924648 @default.
• W4379282384 hasFunder F4320319515 @default.
• W4379282384 hasIssue "16_suppl" @default.
• W4379282384 hasLocation W43792823841 @default.
• W4379282384 hasOpenAccess W4379282384 @default.
• W4379282384 hasPrimaryLocation W43792823841 @default.
• W4379282384 hasRelatedWork W2001196910 @default.
• W4379282384 hasRelatedWork W2074061081 @default.
• W4379282384 hasRelatedWork W2255758241 @default.
• W4379282384 hasRelatedWork W2329858520 @default.
• W4379282384 hasRelatedWork W2517194109 @default.
• W4379282384 hasRelatedWork W2953684910 @default.
• W4379282384 hasRelatedWork W4205849946 @default.
• W4379282384 hasRelatedWork W4244633258 @default.

• next